Younger children are more responsive to amblyopia treatment

Article

Children aged 7 years and younger are more responsive to amblyopia treatment than those aged between 7 and 13 years.

Children aged 7 years and younger are more responsive to amblyopia treatment than those aged between 7 and 13 years, according to a study featured in Archives of Ophthalmology.

Dr Jonathon M. Holmes and his team, Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA, performed a meta-analysis of 4 recently completed randomized amblyopia treatment. This was done to evaluate the correlation between age and improvement in logMAR amblyopic eye visual acuity.

Each analysis was adjusted for spherical equivalent refractive error in the affected eye, type of amblyopia, baseline amblyopic eye visual acuity, previous amblyopia treatment, study treatment and protocol.

The results demonstrated that children aged between 7 and 13 years had a significantly reduced response rate to amblyopia treatment than children less than 7 years of age. However, no differences were found between those aged 3 to 5 years and those aged between 5 and 7 years with moderate ambylopia. Children aged between 3 to 5 years with severe ambylopia had a greater response to treatment than those aged 5 to 7 years.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.